Risedronate use to attenuate bone loss following sleeve gastrectomy: Results from a pilot randomized controlled trial.
Risedronate use to attenuate bone loss following sleeve gastrectomy: Results from a pilot randomized controlled trial.
复制标题
DOI：
10.1111/cob.12487
复制
发表时间：
2021-12
期刊：
影响因子：
3.3
通讯作者：
Ard JD
中科院分区：
文献类型：
--
作者：
Beavers KM;Beavers DP;Fernandez AZ;Greene KA;Swafford AA;Weaver AA;Wherry SJ;Ard JD
本研究的目的是探讨每月一次口服 150 毫克利塞膦酸盐在预防袖状胃切除术 (SG) 相关骨丢失中的功效。 24 名 SG 患者（56 ± 7 岁，83% 女性，21% 黑人）被随机接受利塞膦酸盐或安慰剂治疗 6 个月，并可选择进行 12 个月评估。结果测量包括双能 X 射线吸收测定法获得的区域骨矿物质密度 (aBMD) 的 6 (n = 21) 和 12 (n = 14) 个月变化。六个月的治疗效果估计[平均值（95% CI）]显示股骨颈[利塞膦酸盐：+0.013 g/cm2 (-0.021, 0.046)与安慰剂：-0.041 g/cm2 (-0.067, -0.015)]和腰椎[利塞膦酸盐：+0.028 g/cm2]组间aBMD存在显着差异(-0.006, 0.063) 对比安慰剂：-0.029 g/cm2 (-0.054, -0.004)]；两者 p ≤ 0.02。术后随访至 12 个月时，在全髋部 [利塞膦酸盐：-0.035 g/cm2 (-0.061, -0.009) 与安慰剂：-0.072 g/cm2 (-0.091, -0.052)] 和腰椎 [利塞膦酸盐：+0.012 g/cm2 (-0.038, -0.038)] 观察到不同的 aBMD 治疗效果。 0.063) 对比安慰剂：-0.052 g/cm2 (-0.087, -0.017)]；两者 p < 0.05。初步治疗效果估计表明，使用利塞膦酸盐 6 个月可能有效减少 SG 后中轴骨骼的 aBMD 损失，并且在术后 1 年期间基本保持获益。需要来自充分动力试验的验证数据。
The purpose of this study was to explore the efficacy of 150 mg once monthly oral risedronate use in the prevention of sleeve gastrectomy (SG) associated bone loss. Twenty-four SG patients (56 ± 7 years, 83% female, 21% black) were randomized to risedronate or placebo for 6 months, with an optional 12-month assessment. Outcome measures included 6 (n = 21) and 12 (n = 14) month change in dual energy x-ray absorptiometry-acquired regional areal bone mineral density (aBMD). Six-month treatment effect estimates [mean (95% CI)] revealed significant between group aBMD differences at the femoral neck [risedronate: +0.013 g/cm2 (−0.021, 0.046) vs. placebo: −0.041 g/cm2 (−0.067, −0.015)] and lumbar spine [risedronate: +0.028 g/cm2 (−0.006, 0.063) vs. placebo: −0.029 g/cm2 (−0.054, −0.004)]; both p ≤ 0.02. When followed postoperatively to 12 months, differential aBMD treatment effects were observed at the total hip [risedronate: −0.035 g/cm2 (−0.061, −0.009) vs. placebo: −0.072 g/cm2 (−0.091, −0.052)] and lumbar spine [risedronate: +0.012 g/cm2 (−0.038, 0.063) vs. placebo: −0.052 g/cm2 (−0.087, −0.017)]; both p < 0.05. Preliminary treatment effect estimates signal 6 months of risedronate use may be efficacious in reducing aBMD loss at the axial skeleton post-SG, with benefit largely maintained throughout the 1-year postoperative period. Confirmatory data from an adequately powered trial are needed.